Hydrochlorothiazide

Introduction Overview

Generic Name

hydrochlorothiazide

Brand Name

HydroDIURIL, Esidrix, Microzide

Dosage Form

oral capsule (12.5 mg), oral tablet (12.5 mg; 25 mg; 50 mg)

Drug Class

Thiazide diuretics

Pharmacokinetics

Absorption: Hydrochlorothiazide is rapidly absorbed from the gastrointestinal tract following oral administration, with peak plasma concentrations typically achieved within 1 to 5 hours. The bioavailability ranges widely but is generally about 60-80%. Food intake does not significantly affect the extent of absorption but may slightly delay the time to peak levels. The drug’s absorption is stable across various dosage forms such as tablets and capsules. Clinical data indicate rapid onset of diuretic action correlates with systemic absorption.

Distribution: Once absorbed, hydrochlorothiazide exhibits moderate plasma protein binding (40-70%), primarily to albumin. It distributes into extracellular fluids and penetrates renal tissues where its site of action is located. Volume of distribution has been reported around 0.7 L/kg. The drug crosses the placental barrier but is not extensively lipid-soluble, limiting penetration into the central nervous system. It does not significantly accumulate in red blood cells.

Metabolism: Hydrochlorothiazide undergoes minimal hepatic metabolism. It is largely excreted unchanged by the kidneys, reflecting negligible biotransformation. Only trace amounts of metabolites have been identified. The lack of extensive metabolism reduces the risk of drug interactions mediated by hepatic enzyme systems. Therefore, hepatic impairment does not usually alter its pharmacokinetics markedly.

Elimination: Renal excretion is the primary elimination route for hydrochlorothiazide. Approximately 60-70% of the drug is eliminated unchanged in urine within 24 hours via active tubular secretion and glomerular filtration. The elimination half-life averages 6 to 15 hours but may be prolonged in patients with impaired renal function. The clearance rate varies with renal function status and age. Dose adjustments should be considered for patients with renal insufficiency to avoid accumulation and toxicity.

Dosage Forms

Available Dosage Forms: Hydrochlorothiazide is commercially available in oral capsule form containing 12.5 mg, and oral tablets in strengths of 12.5 mg, 25 mg, and 50 mg. These formulations provide dosing flexibility to tailor therapy according to patient needs and disease severity.

Dosages for Adults and Adolescents: The usual adult dosage for edema management ranges from 25 mg to 100 mg administered orally once or twice daily. Some patients may benefit from intermittent therapy, such as dosing on alternate days or 3 to 5 days weekly, reducing electrolyte imbalance risks. For hypertension, the initial adult dose is typically 25 mg orally once daily, with maintenance doses potentially increasing to 50 mg daily, either as a single dose or divided doses. In conditions such as nephrocalcinosis, initial dosing starts at 25 mg daily with possible escalation to 50 mg twice daily. For diabetes insipidus, oral dosing begins at 50 mg once daily, increasing up to 100 mg as tolerated.

Specific Patient Populations: Pediatric dosing is weight-based and age-specific. For children under 6 months, the dosage can be up to 3 mg/kg/day divided into two doses. Children from 6 months to 2 years receive 1 to 2 mg/kg/day as a single or divided dose, not exceeding 37.5 mg daily. For children aged 2 to 12 years, the same dosing range applies with a maximum of 100 mg daily. Hydrochlorothiazide is not approved for use in individuals under 18 years without close medical supervision. Dose adjustments and careful monitoring are warranted in patients with renal or hepatic impairment. Pregnant or breastfeeding women should consult healthcare providers due to potential risks.

Clinical guidelines emphasize individualized dosing based on therapeutic response, tolerability, and electrolyte monitoring to minimize adverse effects.

Mechanism Of Action

Hydrochlorothiazide primarily acts as a diuretic by inhibiting sodium and chloride reabsorption in the distal convoluted tubule of the nephron. It blocks the Na+/Cl- symporter, leading to increased excretion of sodium, chloride, and consequently water, reducing plasma volume and thereby decreasing blood pressure. This natriuretic effect helps alleviate edema associated with congestive heart failure, cirrhosis, and certain kidney disorders.

On the cellular level, hydrochlorothiazide reduces the reabsorption workload of nephrons, which decreases extracellular fluid volume and reduces peripheral vascular resistance over time. This dual effect contributes to its antihypertensive properties. Additionally, by lowering plasma volume and cardiac output initially, it facilitates long-term modulation of vascular tone and remodeling.

Biochemically, the loss of sodium and water induces secondary effects on electrolyte handling, including potassium loss and increased calcium reabsorption. This calcium-sparing effect distinguishes thiazides from other diuretics, making hydrochlorothiazide useful in managing nephrolithiasis related to hypercalciuria.

Comparatively, unlike loop diuretics that act on the thick ascending limb of Henle’s loop, hydrochlorothiazide’s site of action is more distal, leading to less potent diuresis but sustained antihypertensive effect. Clinical studies confirm its efficacy in lowering blood pressure and reducing cardiovascular morbidity as monotherapy or in combination with other agents.

Pharmacological Actions

Inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting diuresis.
Reduces extracellular fluid volume, lowering blood pressure and edema.
Enhances calcium reabsorption in the distal nephron, aiding in the prevention of calcium kidney stones.
Lowers peripheral vascular resistance with chronic administration, contributing to antihypertensive effects.
Induces potassium loss, necessitating electrolyte monitoring during therapy.
Decreases plasma volume, reducing cardiac preload and afterload.
Modulates renal tubular function impacting electrolyte and acid-base balance.
Exerts a mild vasodilatory effect secondary to volume depletion.
Influences parathyroid hormone receptor-mediated pathways related to calcium handling.
Has a slower onset and longer duration of antihypertensive effect compared to loop diuretics.
Minimal metabolism with primary renal excretion of unchanged drug.
Acts synergistically with other antihypertensive agents in multi-drug regimens.
Does not significantly affect central nervous system or lipid metabolism at therapeutic doses.
Does not induce sulfonamide allergy in most patients but caution required in sulfa-allergic individuals.
May alter glucose tolerance and lipid profile during chronic treatment.

Therapeutic Or Clinical Uses

Management of hypertension as monotherapy or in combination with other antihypertensives.
Treatment of edema associated with congestive heart failure, hepatic cirrhosis, or renal disorders.
Control of edema caused by steroid or estrogen therapy.
Prevention and management of nephrolithiasis by reducing urinary calcium excretion.
Adjunctive therapy in nephrocalcinosis.
Treatment of diabetes insipidus due to its paradoxical antidiuretic effect.
Facilitation of sodium depletion in patients requiring volume reduction.
Used in conditions with fluid retention to improve symptoms and reduce complications.
Management of mild to moderate edema in pediatric populations under careful supervision.
Useful for lowering blood pressure in elderly patients with isolated systolic hypertension.
May be employed in combination with potassium-sparing diuretics to minimize hypokalemia.
Preoperative management of hypertension and fluid status optimization.
Incorporated into protocols for managing ascites related to liver disease.
Research exploring utility in reducing calcium stone recurrence.
May be used cautiously during pregnancy with careful risk-benefit assessment.

Side Or Adverse Effects

Electrolyte imbalances such as hypokalemia, hyponatremia, hypomagnesemia, and hypercalcemia.
Dehydration leading to dizziness, light-headedness, and hypotension.
Gastrointestinal disturbances including nausea and vomiting.
Hyperuricemia potentially precipitating or exacerbating gout attacks.
Photosensitivity reactions, increasing the risk of sunburn and skin cancer.
Allergic reactions including rash, hives, or rare severe skin reactions.
Elevation of blood glucose levels, potentially affecting diabetic control.
Muscle cramps and weakness related to electrolyte shifts.
Headache and fatigue during initiation or dosage escalation.
Increase in cholesterol and triglyceride levels during prolonged therapy.
Pancreatitis and hepatic dysfunction reported rarely.
Blurring of vision or eye pain linked with increased intraocular pressure in glaucoma patients.
Blood dyscrasias such as thrombocytopenia or leukopenia on rare occasions.
Polyuria and nocturia contributing to sleep disturbances.
Rarely, photosensitive dermatoses and Stevens-Johnson syndrome.

Precautions

Use caution in patients with impaired renal function; monitor renal parameters regularly.
Monitor serum electrolytes frequently, especially potassium and sodium levels.
Avoid use in patients with anuria or inability to urinate.
Cautiously administer to patients with hepatic impairment or cirrhosis.
Consider risk of dehydration in elderly patients, especially during hot weather or vigorous activity.
Avoid concurrent use with other agents that may cause significant hypotension or electrolyte disturbances without monitoring.
Alert physician if history of sulfa allergy is present; cross-reactivity is possible but uncommon.
Patients with gout require monitoring for hyperuricemia and gout exacerbations.
Pregnant or nursing mothers should avoid use unless clearly needed and under medical supervision.
Use caution in diabetic patients due to potential hyperglycemic effects.
Monitor blood pressure regularly to avoid excessive hypotension.
Advise patients to avoid alcohol which may enhance adverse effects.
Ensure adequate hydration, but avoid excessive fluid intake which may exacerbate electrolyte imbalance.
Warn patients about photosensitivity and advise use of sun protection.
Avoid abrupt discontinuation to prevent rebound hypertension or edema.

Warnings

Contraindicated in patients with anuria or hypersensitivity to hydrochlorothiazide or sulfonamide-derived drugs.
Risk of severe electrolyte disturbances leading to cardiac arrhythmias and muscle dysfunction.
Potential for severe dehydration resulting in hypotension and acute renal failure.
Increased risk of skin cancer with long-term use; recommend regular skin examinations.
May exacerbate systemic lupus erythematosus symptoms.
Use with caution in patients with biliary or cirrhotic liver disease.
Photosensitivity can lead to severe dermatologic reactions.
Risk of precipitating or worsening diabetes mellitus.
Caution in patients with electrolyte imbalances or disorders of parathyroid gland.
Potential for pancreatitis as a rare adverse effect.
Avoid use in pregnancy unless benefits outweigh risks; possible risk of neonatal jaundice and other complications.
May cause electrolyte imbalances that can precipitate neuromuscular symptoms or cardiac arrhythmias.
Patients should be warned about dizziness or fainting related to orthostatic hypotension.
Discontinue prior to surgery if advised by surgeon due to fluid and electrolyte management concerns.
Hydrochlorothiazide may potentiate the effects of other antihypertensives causing profound hypotension.

Contraindication

Known hypersensitivity to hydrochlorothiazide or other sulfonamide-derived drugs.
Anuria or inability to produce urine.
Severe renal impairment without adequate urine output.
Hypersensitivity to thiazide diuretics.
Concomitant use with other agents contraindicated in electrolyte disturbances without monitoring.
History of hypersensitivity reactions such as angioedema related to hydrochlorothiazide.
Pregnancy and breastfeeding unless clearly indicated and under supervision.
Patients with severe hyponatremia or hypokalemia unless corrected before therapy.
Use contraindicated in patients with a history of aplastic anemia related to diuretics.
Severe hypercalcemia.
Dehydration or severe volume depletion contraindicates hydrochlorothiazide use.
Patients with marked hepatic dysfunction and progressive liver disease.
History of acute gout attacks where thiazide use may exacerbate condition.
Known glucose-6-phosphate dehydrogenase (G6PD) deficiency with caution due to risk of hemolysis.
Use discouraged in neonates and infants under 18 years without specialist guidance.

Drug Interactions

Concurrent use with NSAIDs (e.g., ibuprofen, naproxen, celecoxib) may reduce diuretic and antihypertensive efficacy and increase renal toxicity risk.
Lithium excretion may be decreased, leading to lithium toxicity when combined with hydrochlorothiazide.
Cholestyramine and colestipol may impair absorption of hydrochlorothiazide if administered concurrently.
Combination with insulin or oral hypoglycemics may alter glucose control requiring dose adjustments.
Potentiation of other antihypertensive drugs leading to enhanced blood pressure lowering effect; risk of hypotension.
Corticosteroids may exacerbate electrolyte imbalance by increasing potassium loss.
Drugs causing QT prolongation may have enhanced cardiac risks when combined with potential hydrochlorothiazide-induced electrolyte abnormalities.
Alcohol and CNS depressants may increase risk of hypotension, dizziness, and syncope.
Use with bradycardic agents and antiarrhythmics may require careful monitoring due to electrolyte shifts affecting cardiac rhythm.
May reduce the renal clearance of methotrexate, increasing its toxicity.
Concomitant use with amphotericin B or other nephrotoxic agents can increase risk of renal impairment and hypokalemia.
Agents that alter renal function may modify hydrochlorothiazide elimination and efficacy.
Avoid excessive concurrent use with potassium supplements or potassium-sparing diuretics without monitoring to prevent hyperkalemia.
Use with digitalis glycosides requires caution due to risk of arrhythmias secondary to potassium imbalances.
May enhance the hypotensive effect of other vasodilators and beta-blockers.

Preparations Of The Drug

Oral capsule containing hydrochlorothiazide 12.5 mg.
Oral tablets available in strengths of 12.5 mg.
Oral tablets available in strengths of 25 mg.
Oral tablets available in strengths of 50 mg.
Commercially marketed under brand names such as HydroDIURIL, Esidrix, Microzide.
Available as generic hydrochlorothiazide formulations in various strengths.
Supplied as standard oral dosage forms for convenient once or twice daily administration.
Packaging includes child-resistant bottles to ensure safe storage.
Often available in combination with other antihypertensive agents (not covered here).
Manufactured according to regulatory standards with consistent bioavailability.
Formulated for stability at room temperature away from moisture, heat, and freezing.
Dosage forms designed to allow for flexible titration according to clinical response.
Patient information leaflets included detailing administration, side effects, and precautions.
Formulated without excipients known to cause significant allergic reactions in general population.
Widely available across multiple countries with established quality control.